Gerald M. Ostrov - Jan 15, 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Director
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol
ENTX
Transactions as of
Jan 15, 2025
Transactions value $
$0
Form type
4
Date filed
1/17/2025, 04:32 PM
Previous filing
Oct 4, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Award $0 +8.04K +20.66% $0.00 46.9K Jan 15, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +28.5K $0.00 28.5K Jan 15, 2025 Ordinary Shares, par value NIS 0.0000769 per share 28.5K $2.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.
F2 These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.